drugset / Trial / NCT01736514

A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout

NCT01736514

Phase 3 Completed 109 enrolled Astellas Pharma Taiwan, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, open label, randomized, allopurinol-controlled, parallel-design study. Approximately 120 subjects will be randomly assigned in 1:1 ratio to receive febuxostat, or allopurinol for subjects with gout.

Timeline

Start
2011-03
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule Oral
Subject Febuxostat Small molecule Oral

Indications